Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer

Phase II, Multicenter, Open-label, Randomized Study evaluating neoadjuvant chemotherapy (FOLFOX4) in patients with stage II and III colorectal cancer with standard chemoradiation Defined by Magnetic Resonance Imaging

Trial Details

NCT ID
NCT05378919
Phase
PHASE2
Sponsor
Lithuanian University of Health Sciences
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Radiotherapy 50 Gy
  • Fluorouracil/folic acid
  • Chemotherapy in regimen with Oxaliplatin, fluorouracil, folinic acid (FOLFOX4)
Locations (sample)
  • Kaunas, Lithuania|54.90156,23.90909

Key Eligibility Criteria

  • diagnosed with rectal adenocarcinoma;
  • radiologically measurable tumor size;
  • general condition (ECOG 0-2 points);
  • stage II or III rectal tumor clinically (pelvic MRI and endorectal ultrasound),

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →